Abbvie Inc (ABBV) — Who's Buying and Selling (13F, Q2 2026)

ABBV ranks #17 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

4247 institutions disclose a position in ABBV, but none treat it as a major bet — even Federated Hermes, Inc., its most concentrated holder, allocates just 1.6% of its own portfolio to it.

Fisher Asset Management, LLC has added to its ABBV position for two straight quarters, increasing it by $2.2B to reach $2.4B today.

Wellington Management Group LLP has trimmed its ABBV position for two straight quarters, cutting it by $2.1B while still holding $1.3B.

ABBV is up 0.7% today, and institutions have been net buyers of $125.8B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ABBV posted net income of $6.3B over the trailing twelve months, and currently trades at a P/E of 73.5.

• Profitable — net income of $6.3B over the trailing twelve months
• Revenue grew 10.4% year over year
• Net income improved year over year, from $3.8B to $6.3B
• Generated $19.0B in positive operating cash flow
• Current ratio of 0.67x — below the conventional 1.5x liquidity buffer
• Total liabilities currently exceed total assets (negative shareholder equity)